• Eurofins expects 2026 organic growth below its previous mid-single-digit target, reflecting sluggish markets and clinical programs not restarting this year.
• Nine-month organic growth reached 3%, with third-quarter growth accelerating to 3.5%.
• Annualized acquisition revenue is expected to exceed the previous €250 million target, including Element’s North America Life Sciences Testing Services business.
• Adjusted EBITDA margin should exceed 2025’s 22.5%, progressing toward the unchanged 24% target for 2027.
• Mid-single-digit organic growth remains expected for 2027; unchanged 2026 cash-flow guidance calls for higher free cash flow with strong cash conversion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eurofins Scientific SE published the original content used to generate this news brief via Business Wire (Ref. ID: 20261020427998) on October 21, 2026, and is solely responsible for the information contained therein.